Liquidia (NASDAQ:LQDA) Director Stephen Bloch Sells 82,736 Shares

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 82,736 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $64.97, for a total value of $5,375,357.92. Following the completion of the transaction, the director owned 1,787,306 shares in the company, valued at $116,121,270.82. This represents a 4.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Liquidia Stock Up 3.3%

Shares of LQDA stock traded up $2.05 during trading hours on Monday, reaching $63.90. The company had a trading volume of 3,158,786 shares, compared to its average volume of 1,717,868. Liquidia Corporation has a 12 month low of $11.85 and a 12 month high of $66.78. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The business has a fifty day simple moving average of $46.78 and a 200-day simple moving average of $39.64. The company has a market cap of $5.68 billion, a price-to-earnings ratio of 456.46 and a beta of 0.58.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The company had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. The business’s quarterly revenue was up 4187.1% compared to the same quarter last year. On average, research analysts expect that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently commented on LQDA. Jefferies Financial Group reaffirmed a “buy” rating and set a $60.00 price target on shares of Liquidia in a research report on Monday, May 11th. Lifesci Capital raised Liquidia to a “strong-buy” rating in a research report on Thursday, March 5th. Needham & Company LLC raised their target price on Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research report on Tuesday, April 21st. Finally, Wall Street Zen raised Liquidia from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 16th. Three equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Liquidia presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.63.

Institutional Trading of Liquidia

Large investors have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. purchased a new stake in Liquidia in the fourth quarter worth $25,000. Covestor Ltd grew its position in shares of Liquidia by 41.9% in the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after purchasing an additional 359 shares in the last quarter. Skandinaviska Enskilda Banken AB publ purchased a new position in shares of Liquidia in the third quarter valued at $30,000. FNY Investment Advisers LLC purchased a new position in shares of Liquidia in the third quarter valued at $34,000. Finally, NewEdge Advisors LLC purchased a new position in shares of Liquidia in the second quarter valued at $25,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).